Drugs / Atrovent Respimat (20 mcg)
last change Feb 2010 re-read 2 minutes ago

Atrovent Respimat (20 mcg)

Developed for
chronic obstructive pulmonary disease
Investigated by
Boehringer Ingelheim

Trials 1 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00400153 Nov 2006 → Apr 2008 chronic obstructive pulmonary disease Boehringer Ingelheim Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Atrovent Respimat (20 mcg) ClinicalTrials.gov intervention name — accepted as the source's own label NCT00400153
Route Inhaled “ipratropium bromide (20mcg) Respimat inhaler” PMID 20172704 Feb 2010